Recent News

• 01.27.2026 - Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23
• 01.15.2026 - Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia
• 01.12.2026 - Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue
• 12.31.2025 - Axsome Therapeutics Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for AXS-05 for the Treatment of Alzheimer’s Disease Agitation
• 12.31.2025 - Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA Submission

Recent Filings

• 01.23.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.23.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.22.2026 - 144 Report of proposed sale of securities
• 01.21.2026 - 144 Report of proposed sale of securities
• 01.12.2026 - EX-99.1 EX-99.1
• 01.12.2026 - 8-K Current report
• 01.07.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.07.2026 - 144 Report of proposed sale of securities
• 01.06.2026 - 144 Report of proposed sale of securities
• 01.05.2026 - 144 Report of proposed sale of securities